Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
Kohei Shitara(National Cancer Center Hospital East), Sun Young Rha(Yonsei University), Lucjan Wyrwicz(The Maria Sklodowska-Curie National Research Institute of Oncology), Takashi Oshima(Kanagawa Prefectural Hospital Organization), Nina Karaseva, M. A. Osipov(Leningrad Regional Cancer Center), Hisateru Yasui(Kobe City Medical Center General Hospital), Hiroshi Yabusaki(Niigata Cancer Center Hospital), S. G. Afanasyev(Research Institute of Medical Genetics of Russian Academy of Medical Sciences), Young Kyu Park(Chonnam National University Hwasun Hospital), Salah-Eddin Al-Batran(Krankenhaus Nordwest), Takaki Yoshikawa(National Cancer Center Hospital East), Patricio Yañez(Universidad de La Frontera), Maria Di Bartolomeo(Fondazione IRCCS Istituto Nazionale dei Tumori), Sara Lonardi(Istituti di Ricovero e Cura a Carattere Scientifico), Josep Tabernero(Vall d'Hebron Hospital Universitari), Eric Van Cutsem(KU Leuven), Yelena Y. Janjigian(Cornell University), Do‐Youn Oh(Seoul National University), Jianming Xu(Chinese PLA General Hospital), Xiao Fang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Chie‐Schin Shih(Merck & Co., Inc., Rahway, NJ, USA (United States)), Pooja Bhagia(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yung‐Jue Bang(Seoul National University)
Cited by 329
Abstract
Related Papers
No related papers found
Powered by citation graph analysis